Simplified analogues of the potent human amylase inhibitor montbretin A were synthesised and shown to bind tightly, K I ¼ 60 and 70 nM, with improved specificity over medically relevant glycosidases, making them promising candidates for controlling blood glucose. Crystallographic analysis confirmed similar binding modes and identified new active site interactions.
The healthcare burden of diabetes mellitus has steadily risen over the past century, with an increase from 108 million adult cases worldwide in 1980 to 422 million cases in 2014. 1 Strikingly, type II diabetes accounts for 90-95% of all cases. 2 The inhibition of carbohydrate catabolism has been explored as a means of mediating post-prandial blood glucose levels for the treatment of type II diabetes. 3 Targeting of carbohydrate catabolism provides two benets: beyond directly modulating blood glucose levels it can also promote weight loss in prediabetic individuals to prevent the onset of diabetes. Miglitol, voglibose and acarbose are three inhibitors of carbohydrate catabolism that are currently in medical use. These compounds act as inhibitors of the mammalian gut a-glucosidases, thereby mediating post-prandial blood glucose levels. 4 While effective in preventing hyperglycemia, the resulting displacement of di-and tri-saccharides into the lower gut produces unwanted side effects arising from their strong osmotic effects within the large intestine and their rapid processing by anaerobic bacteria, resulting in diarrhea, nausea, and abdominal discomfort. 5 Human pancreatic a-amylase (HPA) catalyzes the endohydrolysis of ingested starches into maltose and maltotriose 6 and its activity has been positively correlated with post-prandial blood glucose levels. Consequently the targeted inhibition of this enzyme has been highlighted as a means of managing postprandial blood glucose levels while avoiding side effects associated with general a-glucosidase inhibition. 7 Most designs of glycosidase inhibitors have been based upon azasugar scaffolds in which a nitrogen atom replaces O5 or C1 of the sugar ring in the À1 binding site. 8 In this manuscript we explore a completely new pharmacophore for a-amylase inhibition involving stacked phenolic rings that interact closely with the conserved active site carboxylic acids. The parent molecule, montbretin A (MbA), is a complex avonol glycoside produced by Crocosmia croc-osmiiora that acts as a potent and selective inhibitor of HPA (K I ¼ 8 nM). 9 This inhibitor has been tested in ZDF (Zucker diabetic fatty) rats and produced a signicant decrease in blood glucose plasma levels, highlighting this compound as a promising lead for the therapeutic reduction of post-prandial blood glucose levels. 10 However its large-scale extraction and purication from the corms of Crocosmia crocosmiiora is a challenging multistep process and requires a substantial amount of biomass. Consequently the design and synthesis of novel inhibitors based upon MbA's structure has been proposed as a means of generating chemically accessible structures of similar potency and specicity. 11 Montbretin A contains a myricetin avonol core glycosylated at the 3-and 4 0 -positions ( Fig. 1a ). The 3-OH is adorned with an a-linked D-glucopyranosyl-(b-1 / 2)-D-glucopyranosyl-(b-1 / 2)-L-rhamnopyranoside trisaccharide to which a 6-O-caffeic ester is attached on the central D-glucosyl group. The 4 0 -OH of myricetin bears a b-linked L-rhamnopyranosyl-(a-1 / 4)-Dxyloside. X-ray crystallographic analysis of MbA in complex with HPA showed notable points of contact occurring between the enzyme's catalytic residues and MbA's caffeic ester and myricetin A-ring. 11 Meanwhile, minimal interactions were observed with the myricetin B-ring or any of MbA's carbohydrate appendages.
Step-wise chemoenzymatic degradation of MbA had yielded a 'minimum inhibitory structure' termed mini-MbA ( Fig. 1b ). This inhibitor contained only the myricetin avonol and caffeic acid linked through a D-glucopyranosyl-(b-1 / 2)-L-rhamnopyranose disaccharide, and had a K I ¼ 400 nM (ref. 12) towards HPA (lone myricetin and ethyl caffeate have K I ¼ 100 mM and 1.3 mM, respectively 9 ). The retained potency of the simplied mini-MbA structure suggested that a suitable synthetic analogue could achieve equivalent levels of potency, thus mini-MbA was used as inspiration for our synthesis. It was not clear however, whether such a compound would retain the required specicity for HPA over the gut alpha-glucosidases given the active site similarities.
Quercetin was selected to replace myricetin as the avonol core in our analogue synthesis since it, and its glycosylated derivatives, are substantially less expensive than other avonols. Quercetin differs from myricetin only in hydroxylation of the B-ring and, as noted earlier, there are very few interactions between HPA and this ring. 13 In mini-MbA, the caffeic acid and myricetin groups are connected by a disaccharide, which forms a bridge of 7 atoms. This region formed no direct interactions with the enzyme, though it likely provides some conformational constraints. As a result, a variety of different chemical structures could be explored for the linker region. Requirements for linker length and rigidity could be assessed, as well as the possibility of incorporating new functionalities to create favorable interactions with the enzyme.
Quercetin-3-O-rutinoside was used as a convenient and inexpensive starting material for the synthesis since the pre-existing sugar at C3 could be used to differentiate the hydroxyls in a protecting group strategy. Quercetin-3-O-rutinoside was thus reacted with benzyl bromide in the presence of K 2 CO 3 , followed by cleavage of the 3-O-glycoside by treatment with HCl/ethanol to yield benzyl quercetin 2, freeing the 3-OH for subsequent modi-cation. 14 Analogues with simple linkers were rst synthesized to test the basic concept of linking the two phenolics ( Fig. 2 ). Optimal linker length and polarity was then explored through a series containing three, ve, seven and eight atoms. Analogues M01 to M03 contained simple alkyl linkers of three, ve and seven atoms long while M04 contained a similarly exible eightatom triethylene glycol linker. Focus then changed to design of linkers that incorporate appropriate conformational constraints while seeking out favourable interactions of the side chains with active site residues. To that end analogues M05 to M11 were generated containing an amino acid linked to quercetin's 3-OH through a propyl chain (Scheme 1).
Tri-O-benzyl quercetin 2 was functionalized with 1-bromo-3chloropropane, 1-bromo-5-chloropentane, 1-bromo-7azidoheptane, or 1-bromo-8-azido-triethylene glycol depending on the analogue synthesized. Treatment with tetrabutylammonium azide produced a terminal azide, which was reduced with trimethylphosphine. In the cases of analogues M01 to M04, this could be coupled directly to caffeic acid through use of activated pentauorophenyl caffeic ester 1. For analogues M05 to M11, the propylamine derivative 4 propyl was coupled to one of six chosen Fmoc-L-amino acids (with appropriate side chain protecting groups) (Scheme 2). 15 The Fmoc group could be deprotected with 20% piperidine in dichloromethane followed by a second coupling with the pentauorophenyl caffeic ester 1. Deprotection of the benzyl ethers and amino acid protecting groups was achieved through treatment with BBr 3 . While this synthesis allowed the construction of a small library of analogues, the nal deprotection step in particular was prohibitively low yielding, posing a signicant barrier to future applications. The continued study of any promising analogues required an improved synthesis, as will be explored below.
The eleven analogues were tested as inhibitors of HPA as shown in Table 1 . Analogues M01 and M02 both had a K I ¼ 4 mM, demonstrating that joining the avonol and caffeic acid groups with a simple linker could increase potency by 25 times compared to the lone avonol (K I $ 100 mM). 9,13 However, these analogues were substantially less potent than mini-MbA, despite having the potential to form all the same interactions within the amylase active site. M03 was no more potent than the lone avonol, suggesting that its three-atom linker was too short to allow for proper orientation of the phenolic moieties in the active site. M04, which contained an eight-atom triethylene glycol-based linker (TEG), also failed to offer a signicant increase in potency over the lone avonol. Despite having a linker of similar length and exibility to those of M01 and M02, the incorporation of a triethylene glycol-based chain in place of a simple alkyl chain led to a 21-fold drop in potency, potentially due to the differences in polarity.
While amino acid based analogues M05, M07, and M08 offered only meagre increases in potency compared to the lone avonol, M06 fared better with a K I ¼ 1 mM, perhaps due to the limited conformational range of its proline pre-organising the ligand for binding.
Introduction of aromatic residues into the linkers also afforded an increase in binding affinity. The phenylalaninebased analogue M09 bound 22-fold tighter than the unfunctionalized glycine-based analogue M05, suggesting that its aromatic side chain likely creates favorable p stacking interactions in the active site, contributing 1.8 kcal mol À1 to binding affinity. Installation of hydroxyl groups onto the phenyl ring, as seen with the tyrosine-based analogue M10 and the DOPA-based analogue M11, produced a further 40 to 47-fold increase in potency relative to M09, equating to a further $2.5 kcal mol À1 contribution to the binding affinity. With inhibition constants of 70 and 60 nM, M10 and M11 bind approximately six times more tightly than the mini-MbA that inspired their synthesis. Thus not only have we replicated the affinity of the natural product with a simple, synthetically accessible analogue, but also we have substantially improved upon its binding affinity.
To gain insights into the binding modes of the best of these analogues, and particularly to understand the greatly improved affinity of M10 and M11, X-ray crystallographic analysis of analogues M06 and M10 in complex with HPA was pursued. The resulting crystal structures (PDBs 6OCN and 6OBX at 1.15 and 1.30Å resolution) revealed the analogues in non-covalent complex within the enzyme active site. Importantly, an overlay of the M06/HPA and M10/HPA structures with that of mini-MbA/HPA showed essentially complete overlap of the avonol and caffeic acyl moieties in each case, simplifying future design (Fig. 3a) .
Proline-containing analogue M06 created all of the polar contacts within the HPA active site that were previously observed with mini-MbA (Fig. 3b) . Hydrogen bonding was observed between the caffeic acid catechol and R195, D197 and E233 of the enzyme. The 7-OH of M06's avonol formed hydrogen bonds with D197 and H201. A hydrogen bond was also observed between the C4 carbonyl of the avonol and the side chain of T163. Meanwhile, the 3 0 -OH of the avonol formed a hydrogen bond with the side chain of H201, as was also observed in the mini-MbA/HPA complex. This indicates that the more cost-effective quercetin was sufficient to form the necessary interactions within the active site. The absence of this 4 0 -O-disaccharide on mini-MbA opens this position up for hydrogen bonding with K200 in the active site, an interaction that is also seen with M06. In addition to these polar contacts, a p-CH stacking interaction appears to form between the proline side chain of M06 and W59 of the enzyme. Despite its high degree of alignment and reproducibility of polar contacts, M06 is still 2.5 times less potent than mini-MbA, highlighting the importance of MbA's glycosidic appendages in stabilization of a pre-stacked conformation.
Analogue M10 also formed all of the same hydrogen bonds within the amylase active site previously observed for mini-MbA and M06 (Fig. 3c ). In addition, and presumably largely responsible for its affinity enhancement, the tyrosine of M10's linker formed hydrogen bonds with the main chain carbonyl and side chain hydroxyl of T163. These are accompanied by a number of CH-p-interactions between the tyrosine side chain and residues W59, Q63, and L165 of the enzyme.
To probe its specicity towards HPA, M10 was tested as an inhibitor of ten other glycosidases, including human intestinal maltase-glucoamylase and sucrase-isomaltase, and two intestinal bacterial a-amylases ( Table 2 ). The analogue showed no inhibitory activity towards these a-glucosidases at a concentration over 100-fold higher than its K I value for HPA. M10 did show some inhibitory activity against the nonrelevant S. cerevisiae a-glucosidase and Agrobacterium bglucosidase. However, the binding affinity of M10 towards yeast a-glucosidase is actually lower than that of lone quercetin (IC 50 ¼ 7 mM). 16 Comparison of these results with those of previous specicity analyses of mini-MbA and MbA indicated that M10 was in fact more selective for HPA over the intestinal glucosidases, since mini-MbA and MbA inhibited sucraseisomaltase and B. brisolvens a-amylase, respectively. 9, 11 This bodes well for the use of M10 as a selective amylase inhibitor. It also implies that this pharmacophore may have restricted application to other glycosidases.
Inhibitor M10 demonstrates highly promising HPA inhibition, however the synthetic route that led to its discovery has a number of shortcomings that would hamper its development as a potential pharmaceutical. As such, an alternative approach was devised (Scheme 3). Selective azide reduction of 3 propyl could be carried out in the presence of 6 to give amide 7, which could then be globally deprotected to give amine 8. Treatment of crude amine 8 with 1 then delivered M10 in 49% yield over four steps, with no purication necessary between steps. This improved procedure delivers M10 in eight steps from rutin (24% overall yield), with further optimization certainly possible. (c) Two different views of the interactions between M10 (pink) and residues of the HPA active site (grey). In addition to the polar contacts formed with the analogue flavonol and catechol, polar contacts occurred between the linker tyrosine and T163 of the enzyme. pbased interactions also occurred between the enzyme and aromatic tyrosine side chain. 
